MEDVi: 2 Employees, $401M Revenue, and an FDA Warning Letter — The Full Story

Two employees. $401M in annual revenue. A run rate of $1.8B in just 14 months. Meanwhile, their biggest competitor Hims & Hers has 2,400 employees and a lower profit margin.

You saw the reel. Here's everything it couldn't fit in 30 seconds — who Matthew Gallagher actually is, how he built MEDVi with AI and his brother, and the FDA warning letter and fraud allegations that complicate the story.

What You'll Learn

Matthew Gallagher's backstory — from a trailer park to a $1.8B run rate

The exact AI stack that replaces hundreds of employees
How MEDVi compares to Hims & Hers on the numbers that matter
The FDA Warning Letter and "fake doctors" allegations
What Sam Altman predicted two years ago — and whether it actually came true

Who Is Matthew Gallagher?

Matthew Gallagher is 41 years old and lives in Los Angeles. He grew up in a trailer park. His uncle gave him a laptop, and he taught himself to code on it.

He studied Computer Science at the University of Cincinnati and later went through Harvard Business School's Executive Education program. But this wasn't his first company.

Before MEDVi, Gallagher ran Watch Gang for eight years (2016-2024) — a watch subscription box business. He was also CEO of Kurtz Media Group and CTO at Angelrush Ventures. The guy had been building and running companies for over a decade before MEDVi existed.

That matters. MEDVi wasn't a lucky first swing. It was built by someone who already knew how to run a business and write code.

How Did MEDVi Start?

In September 2024, Gallagher launched MEDVi with $20,000 of his own money. No investors. No venture capital. No seed round. Twenty thousand dollars.

The prep time was about two months from idea to launch. The business model: GLP-1 telehealth — connecting patients with prescriptions for semaglutide and tirzepatide, the weight-loss drugs that took over the market.

First month: 300 customers.

Six months in: $100M ARR (annual recurring revenue). That's one of the fastest ramps to $100M in startup history.

Fourteen months in: $1.8B run rate. Daily revenue above $3M. Over 500,000 cumulative patients.

And the 2025 full-year revenue number: $401M with a 16.2% net profit margin. That's roughly $65M in net profit.

How Do 2 People Run a $1.8B Business?

This is the part everyone wants to know. MEDVi has two full-time employees:

Matthew Gallagher — founder and CEO

Elliot Gallagher — Matthew's brother and the only other employee

That's it. Everything else is AI agents and outsourced partners.

Here's the stack:

Code — ChatGPT, Claude, and Grok wrote all the platform code. Every feature, every page, every backend system. Gallagher directs the AI; the AI writes the software.

Marketing — Midjourney generates ad creatives. Runway produces video content. No design team. No video production crew.

Customer support — AI agents handle patient inquiries 24/7. No call center. No support tickets sitting in a queue.

Prescription refills — AI agents process refill requests automatically.

Business analytics — AI agents monitor performance metrics in real time.

The monthly cost of all these AI tools? A few hundred dollars.

For the things AI can't do, MEDVi outsources:

Pharmacy fulfillment: OpenLoop Health
Physician licensing: CareValidate
Legal: External law firms

Gallagher told The New York Times: "It's not an AI company. But I did it with AI."

That line captures it. MEDVi is a telehealth company. The product is access to weight-loss medication. But the entire operational infrastructure — the thing that would normally require hundreds of employees — is AI.

Why Is Hims & Hers Losing on Margins?

Hims & Hers (NYSE: HIMS) operates in the same GLP-1 telehealth market. They're a publicly traded company with over 2,400 employees.

Here's the comparison:

Metric	MEDVi	Hims & Hers
Employees	2	2,400+
Net profit margin	16.2%	5.5%
Funding	$20K bootstrap	IPO + public markets
Founded	2024	2017

MEDVi's margin is roughly 3x higher than Hims & Hers. The reason is structural: when your headcount is two people, your operating costs are fundamentally different.

Hims & Hers carries the overhead of a public company — executive salaries, office leases, HR departments, compliance teams, middle management. MEDVi carries the cost of AI subscriptions and outsourcing contracts.

The core difference: Hims owns its infrastructure. MEDVi rents it. Owning gives you control. Renting gives you margins. Both approaches have trade-offs, and those trade-offs show up differently as the company scales.

What's the Problem?

The numbers are real. But so are the problems.

FDA Warning Letter — February 20, 2026

The FDA sent MEDVi an official Warning Letter on February 20, 2026. This is a public document.

Two violations:

Misbranding — MEDVi's website language implied that MEDVi itself was compounding (custom-mixing) semaglutide and tirzepatide. MEDVi is not a compounder. It connects patients with pharmacies that do the compounding.

Implied FDA approval — The website suggested that compounded products had been evaluated or approved by the FDA. Compounded drugs are not FDA-approved products. That's a factual misrepresentation.

"Fake Doctors" and AI Advertising Allegations

News Anyway reported on April 7, 2026 under the headline "MEDVi's Billion-Dollar Lie" — alleging the use of fake doctors and "AI smoke screens" in the company's operations.

The Decoder reported that MEDVi generated billions in revenue using "AI-powered fake advertising."

Drug Discovery and Development pointed out the irony: The New York Times ran a positive profile on MEDVi after the FDA had already issued its warning letter.

None of these allegations have resulted in legal action as of this writing. But they're part of the public record, and anyone evaluating MEDVi's story should know they exist.

What Did Sam Altman Predict Two Years Ago?

In 2024, OpenAI CEO Sam Altman said: "A one-person business worth $1 billion would have been unimaginable without A.I., and now it will happen."

MEDVi is the first large-scale case that fits that prediction. Two people, not one — but the operational structure is closer to Altman's vision than anything else that's emerged so far.

Amjad Masad, CEO of Replit, noted on LinkedIn that Gallagher grew up in a trailer park — framing MEDVi as evidence that AI lowers the barrier to entry for people without traditional resources or connections.

But not everyone is celebrating.

Forrester published a piece titled "Beware the Magical Two-Person $1 Billion AI-Driven Startup" — warning about structural vulnerabilities in sustainability, regulatory compliance, and medical safety when a company this large runs on this few people.

That tension is the real story. AI makes it possible to build at this scale with almost no team. Whether it's wise to do so — especially in healthcare — is a different question.

What Does This Mean for Everyone Else?

For solo founders: The barrier to building a large company dropped. Not to zero — Gallagher had a decade of entrepreneurial experience and knew how to code. But the capital and headcount requirements are fundamentally different from five years ago.

For employees: When two people can generate $401M in revenue, the definition of "necessary headcount" changes across every industry. The jobs that remain are the ones AI can't do or isn't trusted to do.

For investors: The financial profile of an AI-native company looks nothing like traditional startups. No large team to fund. No office to lease. Margins that legacy competitors can't match. But also: regulatory risk that traditional due diligence might not catch.

For regulators: A company can scale to $1.8B in 14 months. Regulatory review cycles aren't built for that speed. The FDA Warning Letter came five months after MEDVi was already processing thousands of patients daily.

MEDVi's story isn't simple. It's a proof of concept and a cautionary tale at the same time. The achievement is real. The questions about how it was achieved are also real. Both things are true.

Follow @easyai.ai for more breakdowns like this.

---

Sources

Mirror Review — Matthew Gallagher MEDVi Profile

---

Want more?

Browse our prompt packs, guides, and automation tools.

Browse products →